|
MechanismPDE5A inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
CMS203片单剂量给药在男性勃起功能障碍(ED)患者中药物效应动力学(PD)的随机、双盲、阳性和安慰剂对照IIa期临床研究
[Translation] A randomized, double-blind, positive and placebo-controlled phase IIa clinical study on the pharmacodynamics (PD) of a single dose of CMS203 tablets in male patients with erectile dysfunction (ED)
主要目的评估不同剂量的CMS203片对阴茎勃起功能障碍的药效学作用,为CMS203片的临床用法、用量提供依据。
[Translation] The main objective is to evaluate the pharmacodynamic effects of different doses of CMS203 tablets on erectile dysfunction and provide a basis for the clinical usage and dosage of CMS203 tablets.
健康成年男性受试者单次和多次口服CMS203片的安全性、耐受性及药代动力学临床试验
[Translation] A clinical trial on the safety, tolerability and pharmacokinetics of single and multiple oral administration of CMS203 tablets in healthy adult male subjects
评估健康成年男性受试者空腹条件下单次和多次口服CMS203片的安全性和耐受性;评估健康成年男性受试者单次和多次口服递增剂量的CMS203片后的药代动力学特征;评估进食对健康成年男性受试者单次口服CMS203片药代动力学的影响。
[Translation] To evaluate the safety and tolerability of single and multiple oral administration of CMS203 tablets in healthy adult male subjects under fasting conditions; to evaluate the pharmacokinetic characteristics of single and multiple oral escalating doses of CMS203 tablets in healthy adult male subjects; and to evaluate the effect of food on the pharmacokinetics of a single oral administration of CMS203 tablets in healthy adult male subjects.
100 Clinical Results associated with Jinan Meiluwei Biotechnology Co., Ltd.
0 Patents (Medical) associated with Jinan Meiluwei Biotechnology Co., Ltd.
100 Deals associated with Jinan Meiluwei Biotechnology Co., Ltd.
100 Translational Medicine associated with Jinan Meiluwei Biotechnology Co., Ltd.